跳至主要内容
临床试验/NCT00823147
NCT00823147已完成1 期

Pain Catastrophizing as a Cause for Systemic Inflammation

Beth Darnall, PhD2 个研究点 分布在 1 个国家目标入组 93 人开始时间: 2009年1月最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
93
试验地点
2
主要终点
Change in anti-inflammatory cytokine levels assessed from immunoassay samples

研究概览

简要总结

Research shows that the immune system is involved in chronic pain. The immune system is involved in the process of inflammation. The investigators are still learning about the factors that cause inflammation, but know it can be measured in the blood. The purpose of this study is to understand how negative thoughts affect the immune system in women with chronic pain.

A sub-study asks subjects to store a blood sample for future research by the PI aimed at identifying genetic markers in women with chronic pain.

详细描述

A main goal of the study is to better understand pain mechanics. Research has linked pro-inflammatory cytokines to the development and progression of pain. Research has also linked female gender with increases in pro-inflammatory cytokines (relative to males) following psychological stress. Therefore, we hypothesize that women in the study who evidence significantly increased pro-inflammatory cytokines following pain catastrophizing may be at risk for the progression of their pain condition.

The sample will be 60 women having chronic musculoskeletal pain (we will enroll up to 75 persons to account for attrition and screen failures but require the usable data of only 60 women). Based on enrollment rates for our previous study, and given our expanded catchment area, we expect to enroll 60 persons within approximately 14 months and to complete the experimental phase of the study within approximately 17 months. The follow-up phase of the study will continue, for as long as participants agree to be followed for up to 10 years.

The study design is a randomized, controlled experiment. Participants are consented and enrolled under the impression that they will undergo one stress experiment day (lasting about 5.5 hours). However, on their study day we will randomize subjects to either be in the control group or the catastrophizing (stress) group.

Screening Visit: The purpose of this visit is to determine eligibility and obtain informed consent. Inclusion and exclusion criteria will be assessed through medical record review, a screening interview, and a hormonal bloodspot kit. A questionnaire will also be given to determine level of depressive symptoms and to assess for suicidality. The hormonal bloodspot kit involves a finger prick and obtaining about 5-6 drops of blood. If lab analysis of this kit determines abnormal hormonal levels, persons will be excluded from further participation in the study. Participants will be given a saliva kit to gather 4 saliva samples at home over the course of one day. Participants will store these saliva samples in their refrigerator. They will either bring in the kit at the time of their study visit or mail the kit in a prepaid box given to them (the hormones in the saliva are shelf stable for up to 3 weeks; we will ask participants to refrigerate the samples if they are not immediately mailing them or bringing them to the study site. In this way we will best ensure that samples will be preserved and usable). All participants enrolled in the study will be under the impression that they will be participating in a catastrophizing experiment during their study day. However, only half of the participants will actually experience the 10-minute stress experiment on experiment day. We have included this minor form of deceit in the protocol so we can control for the anticipatory stress of expecting to experience a negative emotional experiment. We highlight here that the mild deception will occur for only half the sample (those going into the control group) and it represents a decrease in risk for these persons.

Study Visit: This study visit is scheduled to occur during the follicular phase of the menstrual cycle (this phase follows the menstrual period and is easy to predict in our sample of normally menstruating women by using a calendar). If difficulty is encountered in predicting the date of the follicular phase, participants will call the PI or study coordinator when their menstrual period begins to schedule their study date (approximately 5-6 days from onset on menses). All participants arrive in a fasting state, during their follicular phase to control for sex-steroid influences on immunity. 3ml of blood will be drawn for hormone levels. The hormone level will not be analyzed at this time, but saved until the end of the study for analysis, if needed. A complete cardiometabolic panel will be measured via bloodspot. If the subject agrees to take part in the sub study, we will take an additional 10mL of blood for an extra bloodspot card that we will store for future pain/genomic research. Pain ratings will be assessed, and questionnaires will be completed. Standardized meals (with no caffeine) will be served to participants (breakfast, lunch, snacks). An OCTRI research nurse will place an intravenous catheter into the arm of participant's choosing. A Holter heart monitor will be placed on participants by nursing. This is a portable device that measures heart beat. Placement of the leads around the heart involves cleaning the skin. The monitor will remain affixed for the duration of the study visit. At this point participants will be randomized to either be in the control group or in the catastrophizing group using a random number generator. After they are randomized into one of the two groups, the deception will be revealed to the control group, and its rationale explained. Those randomized to the stress group will be informed of the deception, and the rationale for having used it, at the conclusion of the study visit .

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women between the ages 18-70
  • Non-smokers
  • Diagnosed with musculoskeletal chronic pain
  • Normal menstrual cycle or postmenopausal

排除标准

  • Psychosis or suicidality
  • Current Major Depression
  • Former intravenous drug user
  • Needle/blood/injection phobia
  • Limited venous access
  • Sex-steroid dysregulation
  • Self-Reported Pregnancy
  • Fibromyalgia or inflammatory disease, e.g. lupus
  • Active corticosteroid regimen
  • Taking beta blockers
  • Taking oral contraception or hormone therapy

研究组 & 干预措施

Control Group

No Intervention

Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.

Control group: Persons in this group will rest, complete puzzles, read emotionally-neutral material or watch videos provided to them.

Blood draws and saliva samples gathered per protocol time points:

  1. 25 minutes following IV placement (BASELINE- T1)
  2. 25 minutes following baseline T2
  3. 115 minutes (1 hour 55 min) post baseline T3
  4. 175 minutes (2 hours 55 min) post baseline T4
  5. 235 minutes (3 hours 55 min) post baseline T5
  6. 295 minutes (4 hours 55 min) post baseline T6

Pain Catastrophizing Induction Group

Experimental

Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.

Catastrophizing group: 10-minute catastrophizing induction. Participants self-rate their level of emotional distress.

Subsequent blood draws occur per protocol time points:

  1. 25 minutes following IV placement (BASELINE)
  2. 15 minutes post catastrophizing induction (stress experiment)
  3. 90 minutes (1.5 hours) post-induction
  4. 150 minutes (2.5 hours) post-induction
  5. 210 minutes (3.5 hours) post-induction
  6. 270 minutes (4.5 hours) post-induction

干预措施: Pain Catastrophizing Induction (Behavioral)

结局指标

主要结局

Change in anti-inflammatory cytokine levels assessed from immunoassay samples

时间窗: 3.5 hours

Change in pro-inflammatory cytokine levels assessed from immunoassay samples

时间窗: 3.5 hours

次要结局

未报告次要终点

研究者

发起方
Beth Darnall, PhD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Beth Darnall, PhD

Principal Investigator

Oregon Health and Science University

研究点 (2)

Loading locations...

相似试验